Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent

Clinical Cancer Research

Volumn 10, Issue 12 II, 2004, Pages

  Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; GEMCITABINE; HOMOCYSTEINE; NAVELBINE; OXALIPLATIN; PEMETREXED; PLATINUM DERIVATIVE;

ANEMIA; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG MECHANISM; DRUG TARGETING; DYSPNEA; FATIGUE; FOLIC ACID DEFICIENCY; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MESOTHELIOMA; MUCOSA INFLAMMATION; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; VITAMIN DEFICIENCY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; FOLIC ACID; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; NEOPLASMS; PLATINUM COMPOUNDS; THYMIDYLATE SYNTHASE; VITAMIN B 12;

EID: 3042575322     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-040010     Document Type: Conference Paper

References (28)

1. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3-10.
2. Shih C, Mendelsohn LG, Chen VJ, Schultz RM. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998;38:135-52.
3. Zhao R, Babani S, Gao F, Liu L, Goldman ID. The mechanism of transport of the multitargeted antifolate. MTA-LY231514, and its cross-resistance pattern in cell with impaired transport of methotrexate. Clin Cancer Res 2000;6:3687-95.
4. Pratt SE, Emerick RM, Horwit L, et al. Multidrug resistance proteins (MRP) 2 and 5 transport and confer resistance to Alimta. Proc Am Assoc Cancer Res 2002;43:782.
5. Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002;29(6 Suppl 18):3-17.
6. Shih C, Gosset L, Gates S, et al. LY231514 and its polyglutamates exhibit potent inhibition against both human dihydrofolate reductase (DHFR) and thymidylate synthase (TS): multiple folate enzyme inhibition. Ann Oncol 1996;7:85.
7. Schultz RM, Patel VF, Worzalla JF, Shih CA. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999;19:437-43.
8. Schilsky RL. Antimetabolites. In: Perry MC, editor. The chemotherapy source book. Baltimore: Williams & Wilkins; 1992. p. 301-15.
9. Grem JL. Fluorinated pyrimidines. In: Chabner BA, Collins JM, editors. Cancer chemotherapy: principles and practice. Philadelphia: Lippincott; 1990. p. 180-224.
10. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo(2,3-d)pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-2011.
11. Shih C, Thornton DE. Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514). In: Jackman AL, editor, Antifolate drugs in cancer therapy. Totowa, NJ: Humana Press, 1999. p. 183-201
12. Adjei AA. Pemetrexed (Alimta): A novel multitargeted antifolate agent. Expert Rev Anticancer Ther 2003;3:89-100.
13. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J Rev 1993;7:1344-53.
14. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-52.
15. Celio L, Bajetta E, Buzzoni R, et al. Efficacy and toxicity of pemetrexed disodium (ALIMTA) with folic acid (FA) in gastric cancer (abstract 660). Proc Am Soc Clin Oncol 2001;166a.
16. Hammond L, Villalona-Calero M, Eckhardt SG, et al. A phase I and pharmacokinetic (PK) study of the multitargeted antifol (MTA) LY231514 with folic acid (abstract 866). Proc Am Soc Clin Oncol 1998;17:255.
17. Rusthoven J, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first line chemotherapy for patients with advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1999;17:1194-9.
18. Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of pemetrexed disodium in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Ann Oncol 2002;13:737-41.
19. Postmus P, Mattson K, von Pawel J, et al. Phase II trial of MTA (LY231514) in patients (PTS) with non-small cell lung cancer (NSCLC) who relapsed after previous platinum or non-platinum chemotherapy. Eur J Cancer 1999;35(Suppl 4):249.
20. Hanna NH, Shepherd FA, Rosell R, et al. A phase III study of pemetrexed in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy (abstract 2503). Proc Am Soc Clin Oncol 2003;23.
21. Manegold C, Von Pawel J, Pirker R, Malayeri R, Blatter J, Krejcy K. Front-line treatment of advanced non-small cell lung cancer with MTA and cisplatin: a multicenter phase II trial. Ann Oncol 2000;11:435-40.
22. Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson RD, Fisher B, Eisenhauer E. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. Cancer (Phila) 2001;92:595-600.
23. Scaglioti G, Kortsik C, Castellano D, et al. Phase II randomized study of pemetrexed plus carboplatin or oxaliplatin as front-line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer (abstract 2513). Proc Am Soc Clin Oncol 2003;23.
24. Clarke S, Underhill C, White S, et al. Phase II study of pemetrexed and vinorelbine in patients with locally advanced or metastatic non-small cell lung cancer. Ann Oncol 2002;13(Suppl. 5):149.
25. Adjei AA, Erlichman E, Sloan JA, et al. A phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent (MTA) in patients with advanced solid tumors. J Clin Oncol 2000;18:1748-57.
26. Ettinger DS, Monnerat C, Kelly K, et al. Phase II trial of pemetrexed + gemcitabine in patients with advanced non-small cell lung cancer: importance of survival over response (abstract 1243). Proc Am Assoc Clin Oncol 2002;21.
27. Adjei AA, Erlichman C, Thornton D, et al. Synergistic cytotoxicity of MTA (LY231514) and gemcitabine in vitro and in vivo [abstract]. 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy; 1998 June 16-19. Amsterdam, the Netherlands. Ann Oncol, 1998;644.
28. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999;59:3671-6.